神经胶质瘤是最具侵袭性的脑肿瘤类型之一，具有高发病率和死亡率。目前，神经胶质瘤的传统治疗方法，如手术切除、放疗和化疗，效果有限，需要新的方法来改善患者的预后。基于 mRNA 的疫苗代表了一种有前途的癌症治疗策略，包括神经胶质瘤。使用基于 mRNA 的树突状细胞疫苗进行免疫治疗的最新进展在临床前和临床试验中显示出巨大的潜力。树突状细胞是专业的抗原呈递细胞，在启动和调节免疫反应中发挥着至关重要的作用。在这篇综述中，我们总结了基于 mRNA 的胶质瘤疫苗的当前进展，重点关注基于树突状细胞的 mRNA 疫苗的最新进展。我们还讨论了基于 mRNA 的神经胶质瘤临床应用的可行性和安全性。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Gliomas are one of the most aggressive types of brain tumors and are associated with high morbidity and mortality rates. Currently, conventional treatments for gliomas such as surgical resection, radiotherapy, and chemotherapy have limited effectiveness, and new approaches are needed to improve patient outcomes. mRNA-based vaccines represent a promising therapeutic strategy for cancer treatment, including gliomas. Recent advances in immunotherapy using mRNA-based dendritic cell vaccines have shown great potential in preclinical and clinical trials. Dendritic cells are professional antigen-presenting cells that play a crucial role in initiating and regulating immune responses. In this review, we summarize the current progress of mRNA-based vaccines for gliomas, with a focus on recent advances in dendritic cell-based mRNA vaccines. We also discuss the feasibility and safety of mRNA-based clinical applications for gliomas.Copyright © 2024 Elsevier B.V. All rights reserved.